Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$353M |
| 2 |
Microsoft
MSFT
|
+$352M |
| 3 |
Apple
AAPL
|
+$256M |
| 4 |
Alibaba
BABA
|
+$189M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$125M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$82M |
| 2 |
Generac Holdings
GNRC
|
+$33.7M |
| 3 |
Pool Corp
POOL
|
+$32.5M |
| 4 |
Keurig Dr Pepper
KDP
|
+$31M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.28% |
| 2 | Consumer Discretionary | 10.77% |
| 3 | Healthcare | 5.09% |
| 4 | Industrials | 4.03% |
| 5 | Financials | 3.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1501
Lufax Holding
LU
$1.17B
| $325K | ﹤0.01% |
+5,727
| New | +$343K |
|
1502
Blue Owl Capital
OBDC
$5.62B
| $325K | ﹤0.01% |
+25,668
| New | +$325K |
|
|
TWO
1503
Two Harbors Investment
TWO
$1.28B
| $325K | ﹤0.01% |
+12,751
| New | +$303K |
|
1504
Koppers
KOP
$867M
| $324K | ﹤0.01% |
+10,407
| New | +$271K |
|
1505
Park-Ohio Holdings
PKOH
$649M
| $324K | ﹤0.01% |
+10,481
| New | +$264K |
|
1506
Advanced Energy
AEIS
$11B
| $323K | ﹤0.01% |
3,332
-2,757
| -45% | -$235K |
|
|
RAVN
1507
DELISTED
Raven Industries Inc
RAVN
| $323K | ﹤0.01% |
9,758
-1,355
| -12% | -$35.7K |
|
1508
Alpha Pro Tech
APT
$53.3M
| $322K | ﹤0.01% |
+28,879
| New | +$390K |
|
1509
Franklin Electric
FELE
$4.56B
| $322K | ﹤0.01% |
+4,658
| New | +$307K |
|
|
SGMO
1510
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $322K | ﹤0.01% |
20,611
-30,049
| -59% | -$352K |
|
1511
Quince Therapeutics
QNCX
$34.1M
| $321K | ﹤0.01% |
+58
| New | +$514K |
|
|
CNST
1512
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $321K | ﹤0.01% |
+11,132
| New | +$280K |
|
1513
Tilly's
TLYS
$114M
| $320K | ﹤0.01% |
39,184
-3,403
| -8% | -$25.7K |
|
|
WSR
1514
DELISTED
Whitestone REIT
WSR
| $320K | ﹤0.01% |
40,189
+23,764
| +145% | +$171K |
|
1515
Crane NXT
CXT
$2.87B
| $319K | ﹤0.01% |
11,824
-33,987
| -74% | -$749K |
|
1516
ING
ING
$100B
| $319K | ﹤0.01% |
+33,784
| New | +$290K |
|
|
EIGI
1517
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $318K | ﹤0.01% |
33,598
-66,171
| -66% | -$547K |
|
1518
American Public Education
APEI
$846M
| $317K | ﹤0.01% |
+10,388
| New | +$319K |
|
1519
Protagonist Therapeutics
PTGX
$10B
| $317K | ﹤0.01% |
+15,701
| New | +$338K |
|
1520
Stewart Information Services
STC
$2.13B
| $317K | ﹤0.01% |
+6,557
| New | +$299K |
|
1521
Banc of California
BANC
$2.95B
| $316K | ﹤0.01% |
+21,459
| New | +$280K |
|
1522
Gates Industrial Corp
GTES
$6.59B
| $316K | ﹤0.01% |
+24,759
| New | +$310K |
|
1523
Lincoln National
LNC
$8.11B
| $316K | ﹤0.01% |
+6,289
| New | +$267K |
|
1524
Puma Biotechnology
PBYI
$471M
| $313K | ﹤0.01% |
30,501
-7,641
| -20% | -$77.4K |
|
|
TGP
1525
DELISTED
Teekay LNG Partners L.P.
TGP
| $313K | ﹤0.01% |
+27,283
| New | +$310K |
|
Similar funds
Michael Gelband's Q4 2020 Portfolio in Review
As of Q4 2020, Michael Gelband held 2,600 positions worth $10.3B, up 105% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Michael Gelband deployed $4.62B of net new capital in Q4 2020, opening 918 new positions and adding to 493 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Charles Schwab, an estimated $82M trimmed.
- Michael Gelband's largest Q4 2020 buy was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.
- Michael Gelband added most to Amazon in Q4 2020, an estimated $353M increase.
- Michael Gelband's biggest Q4 2020 reduction was Charles Schwab, cutting an estimated $82M.
- Michael Gelband fully exited Eli Lilly in Q4 2020, selling an estimated $21.7M.
- Michael Gelband's ten largest holdings make up 42% of its $10.3B portfolio in Q4 2020.
- Michael Gelband opened 918 new positions and closed 701 in Q4 2020.
- Michael Gelband's portfolio value rose 105% quarter-over-quarter to $10.3B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.